Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States.

@article{Angus2003CosteffectivenessOI,
  title={Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States.},
  author={Derek C. Angus and Gilles Clermont and R Scott Watson and Walter T. Linde-Zwirble and Reese H. Clark and Mark S. Roberts},
  journal={Pediatrics},
  year={2003},
  volume={112 6 Pt 1},
  pages={1351-60}
}
OBJECTIVE Two recent randomized controlled trials (RCTs) reported that inhaled nitric oxide (iNO) decreased the incidence of extracorporeal membrane oxygenation (ECMO) or death in term and near-term newborns with hypoxic respiratory failure. Our objective was to estimate the cost-effectiveness ratio of iNO in this population. METHODS We studied 1000 simulation cohorts (n = 483 for each cohort) of term/near-term newborns with hypoxemic respiratory failure. We conducted our study following US… CONTINUE READING